Heather Lau, MD, Director, Lysosomal Storage Disease Program and Associate Director, Division of Neurogenetics at NYU Langone Health, provides an overview of how to manage a person with a mucopolysaccharidosis (MPS) condition during the current COVID-19 pandemic.
MPSs are a group of rare, inherited lysosomal storage disorders that are clinically characterized by abnormalities in multiple organ systems and reduced life expectancy. Many MPS conditions have symptoms, and treatment options, that can complicate how these patients are managed during the current pandemic.
In this webinar, Dr. Lau explains the:
- Multisystemic manifestations of COVID-19
- Impact of COVID19 on MPS Diseases
- Impact of COVID19 on access to therapy
- Exposure to COVID-19. What to do?
- Ethical considerations of COVID-19 in MPS patients
To learn more about the various MPS conditions [MPS1 (Hurler syndrome), MPS II (Hunter syndrome), MPS III (Sanfilippo syndrome), MPS IV (Morquio syndrome), MPS VI (Maroteaux-Lamy syndrome), and MPS VII (Sly syndrome)], visit https://checkrare.com/mps or https://mpssociety.org/
